Anatara LifesciencesASX:ANR EV-to-FCF is -3.18 as of Jul. 03, 2026. The stock has 5 warning signs investors should review. Among 332 Biotechnology companies, Anatara Lifesciences ranks worse than 301204.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anatara Lifesciences's Enterprise Value is A$3.47 Mil.
Anatara Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.09 Mil. Therefore, Anatara Lifesciences's EV-to-FCF for today is -3.18.
The historical rank and industry rank for Anatara Lifesciences's EV-to-FCF or its related term are showing as below:
ASX:ANR'
s EV-to-FCF Range Over the Past 10 Years
Min: -182.92 Med: -0.83 Max: 2.12
Current: -3.18
During the past 11 years, the highest EV-to-FCF of Anatara Lifesciences was 2.12. The lowest was -182.92. And the median was -0.83.
ASX:ANR's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs ASX:ANR: -3.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anatara Lifesciences's PE Ratio (TTM) for today is calculated as:
Anatara Lifesciences's share price for today is A$0.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anatara Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.006.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Anatara Lifesciences EV-to-FCF Related Terms
Anatara Lifesciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Anatara Lifesciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anatara Lifesciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anatara Lifesciences EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Anatara Lifesciences's EV-to-FCF falls into.
Anatara Lifesciences's current Enterprise Value is A$3.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anatara Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anatara Lifesciences (ASX:ANR) has a EV-to-FCF of -3.18 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anatara Lifesciences and its competitors. According to the industry distribution chart, Anatara Lifesciences ranks #999999 out of 332 companies in the Biotechnology industry.
Is Anatara Lifesciences' EV-to-FCF too high?
Anatara Lifesciences' current EV-to-FCF is -3.18. Based on the distribution chart, Anatara Lifesciences ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Anatara Lifesciences' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anatara Lifesciences ranks #999999 out of 332 companies for EV-to-FCF. This places Anatara Lifesciences in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anatara Lifesciences and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anatara Lifesciences's current EV-to-FCF is -3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatara Lifesciences stock overvalued right now?
Anatara Lifesciences (ASX:ANR) has a current EV-to-FCF of -3.18. The current EV-to-FCF is -3.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Anatara Lifesciences (ASX:ANR), the current EV-to-FCF is -3.18 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ANR has been successfully added to your 